Details of the Drug

General Information of Drug (ID: DM2EN6G)

Drug Name
Propantheline
Synonyms
Corrigast; Ercorax; Ercotina; Ketaman; Kivatin; Neometantyl; Neopepulsan; Pantas; Pantheline; Pervagal; Probanthine; Probantine; Prodixamon; Propantel; Propanthel; Propanthelinium; Propanthelinum; Bromure de propantheline; Bromuro de proantelina; PROPANTHELINE BROMIDE; Propantelina bromuro; Propantelina bromuro [DCIT];Propanthelini bromidum; P 8891; Bromure de propantheline [INN-French]; Bromuro de proantelina [INN-Spanish]; Pro-Banthine; Pro-Gastron; Propanthelini bromidum [INN-Latin]; SC-3171; Pro-Banthine (TN);Propantheline bromide (JP15/USP/INN); Propantheline bromide [USAN:INN:BAN:JAN]; Diisopropyl(2-hydroxyethyl)methylammonium bromide xanthene-9-carboxylate; Xanthene-9-carboxylic acid, ester with (2-hydroxyethyl)diisopropylmethylammonium bromide; Ammonium, (2-hydroxyethyl)diisopropylmethyl-, xanthene-9-carboxylate (ester); Ammonium, diisopropyl(2-hydroxyethyl)methyl-, bromide, xanthene-9-carboxylate; Methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium; Methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium bromide; N-methyl-N-(1-methylethyl)-N-{2-[(9H-xanthen-9-ylcarbonyl)oxy]ethyl}propan-2-aminium bromide; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate bromide; 2-Hydroxyethyl]diisopropylmethyl-ammonium bromide xanthene-9-carboxylate; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide (1:1)
Indication
Disease Entry ICD 11 Status REF
Excessive sweating EE00.Z Approved [1]
Peptic ulcer DA61 Approved [2]
Stomach ulcer DA60.Z Approved [1]
Therapeutic Class
Antispasmodics
Affected Organisms
Humans and other mammals
ATC Code
A03AB05: Propantheline
A03AB: Synthetic anticholinergics, quaternary ammonium compounds
A03A: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
A03: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
A: ALIMENTARY TRACT AND METABOLISM
A03AB05: Propantheline
A03AB: Synthetic anticholinergics, quaternary ammonium compounds
A03A: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
A03: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
A: ALIMENTARY TRACT AND METABOLISM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 368.5
Logarithm of the Partition Coefficient (xlogp) 4.2
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Elimination
3.5% of drug is excreted from urine in the unchanged form [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.8231 micromolar/kg/day [4]
Water Solubility
The ability of drug to dissolve in water is measured as 50 mg/mL [3]
Chemical Identifiers
Formula
C23H30NO3+
IUPAC Name
methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium
Canonical SMILES
CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C
InChI
InChI=1S/C23H30NO3/c1-16(2)24(5,17(3)4)14-15-26-23(25)22-18-10-6-8-12-20(18)27-21-13-9-7-11-19(21)22/h6-13,16-17,22H,14-15H2,1-5H3/q+1
InChIKey
VVWYOYDLCMFIEM-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4934
ChEBI ID
CHEBI:8481
CAS Number
298-50-0
UNII
1306V2B0Q8
DrugBank ID
DB00782
TTD ID
D0V5ZZ
ACDINA ID
D00563
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor M1 (CHRM1) TTZ9SOR ACM1_HUMAN Antagonist [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Excessive sweating
ICD Disease Classification EE00.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Muscarinic acetylcholine receptor M1 (CHRM1) DTT CHRM1 5.59E-01 0.19 0.41
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Propantheline (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Bethanechol DMCLHO0 Moderate Antagonize the effect of Propantheline when combined with Bethanechol. Abnormal micturition [MF50] [6]
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Propantheline due to adsorption of Sodium bicarbonate. Acidosis [5C73] [7]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Propantheline and Oliceridine. Acute pain [MG31] [8]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Propantheline and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [9]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Propantheline and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [9]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Propantheline and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [10]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Propantheline and Memantine. Alzheimer disease [8A20] [10]
Rivastigmine DMG629M Moderate Antagonize the effect of Propantheline when combined with Rivastigmine. Alzheimer disease [8A20] [11]
Donepezil DMIYG7Z Moderate Antagonize the effect of Propantheline when combined with Donepezil. Alzheimer disease [8A20] [11]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Propantheline and Desipramine. Attention deficit hyperactivity disorder [6A05] [10]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Propantheline and Cariprazine. Bipolar disorder [6A60] [10]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Propantheline and Loperamide. Bowel habit change [ME05] [12]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Propantheline when combined with Acetylcholine. Cataract [9B10] [13]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Propantheline and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [14]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Propantheline and Tiotropium. Chronic obstructive pulmonary disease [CA22] [14]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Propantheline and Revefenacin. Chronic obstructive pulmonary disease [CA22] [14]
Dihydrocodeine DMB0FWL Moderate Additive CNS depression effects by the combination of Propantheline and Dihydrocodeine. Chronic pain [MG30] [15]
Alfentanil DMVO0UB Moderate Additive antimotility effects by the combination of Propantheline and Alfentanil. Corneal disease [9A76-9A78] [16]
Remifentanil DMZTXCH Moderate Additive CNS depression effects by the combination of Propantheline and Remifentanil. Corneal disease [9A76-9A78] [8]
Arbutamine DMCY8AF Moderate Increased risk of rapid heart rate by the combination of Propantheline and Arbutamine. Coronary atherosclerosis [BA80] [17]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Propantheline and Cyclobenzaprine. Depression [6A70-6A7Z] [10]
Isocarboxazid DMAF1NB Minor Additive anticholinergic effects by the combination of Propantheline and Isocarboxazid. Depression [6A70-6A7Z] [10]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Propantheline and OPC-34712. Depression [6A70-6A7Z] [10]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Propantheline and Clomipramine. Depression [6A70-6A7Z] [10]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Propantheline and Doxepin. Depression [6A70-6A7Z] [10]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Propantheline and Maprotiline. Depression [6A70-6A7Z] [10]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Propantheline and Mepenzolate. Digestive system disease [DE2Z] [10]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Propantheline and Oxybutynine. Discovery agent [N.A.] [10]
Zonisamide DM0DTF7 Major Additive CNS depression effects by the combination of Propantheline and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [18]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Propantheline and Diphenhydramine. Episodic vestibular syndrome [AB31] [10]
Nadolol DMW6GVL Moderate Antagonize the effect of Propantheline when combined with Nadolol. Essential hypertension [BA00] [19]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Propantheline and Solifenacin. Functional bladder disorder [GC50] [10]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Propantheline and Tolterodine. Functional bladder disorder [GC50] [10]
Ketoconazole DMPZI3Q Moderate Decreased absorption of Propantheline due to altered gastric pH caused by Ketoconazole. Fungal infection [1F29-1F2F] [20]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Propantheline when combined with Pilocarpine. Glaucoma [9C61] [6]
Carvedilol DMHTEAO Moderate Altered absorption of Propantheline due to GI dynamics variation caused by Carvedilol. Heart failure [BD10-BD1Z] [19]
Chlorothiazide DMLHESP Minor Altered absorption of Propantheline due to GI dynamics variation caused by Chlorothiazide. Heart failure [BD10-BD1Z] [21]
Acebutolol DM0TI4U Moderate Altered absorption of Propantheline due to GI dynamics variation caused by Acebutolol. Hypertension [BA00-BA04] [19]
Penbutolol DM4ES8F Moderate Antagonize the effect of Propantheline when combined with Penbutolol. Hypertension [BA00-BA04] [7]
Nebivolol DM7F1PA Moderate Antagonize the effect of Propantheline when combined with Nebivolol. Hypertension [BA00-BA04] [19]
Pindolol DMD2NV7 Moderate Antagonize the effect of Propantheline when combined with Pindolol. Hypertension [BA00-BA04] [19]
Indapamide DMGN1PW Minor Altered absorption of Propantheline due to GI dynamics variation caused by Indapamide. Hypertension [BA00-BA04] [21]
Trichlormethiazide DMHAQCO Minor Altered absorption of Propantheline due to GI dynamics variation caused by Trichlormethiazide. Hypertension [BA00-BA04] [21]
Hydrochlorothiazide DMUSZHD Minor Altered absorption of Propantheline due to GI dynamics variation caused by Hydrochlorothiazide. Hypertension [BA00-BA04] [21]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Propantheline and Belladonna. Infectious gastroenteritis/colitis [1A40] [10]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Propantheline and Amantadine. Influenza [1E30-1E32] [22]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Propantheline and ITI-007. Insomnia [7A00-7A0Z] [10]
R0-93877 DMM4U9G Moderate Antagonize the effect of Propantheline when combined with R0-93877. Irritable bowel syndrome [DD91] [23]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Propantheline and Dicyclomine. Irritable bowel syndrome [DD91] [10]
Physostigmine DM2N0TO Moderate Antagonize the effect of Propantheline when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [11]
Neostigmine DM6T2J3 Moderate Antagonize the effect of Propantheline when combined with Neostigmine. Myasthenia gravis [8C6Y] [24]
Edrophonium DMCRQHB Moderate Antagonize the effect of Propantheline when combined with Edrophonium. Myasthenia gravis [8C6Y] [24]
Ambenonium DMOP0BL Moderate Antagonize the effect of Propantheline when combined with Ambenonium. Myasthenia gravis [8C6Y] [24]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Propantheline and Phenindamine. Nasopharyngitis [CA00] [10]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Propantheline and Dimenhydrinate. Nausea/vomiting [MD90] [10]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Propantheline and Promethazine. Nausea/vomiting [MD90] [10]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Propantheline and Cyclizine. Nausea/vomiting [MD90] [10]
Metoclopramide DMFA5MY Moderate Antagonize the effect of Propantheline when combined with Metoclopramide. Nausea/vomiting [MD90] [25]
Polythiazide DMCH80F Minor Altered absorption of Propantheline due to GI dynamics variation caused by Polythiazide. Oedema [MG29] [21]
Levomethadyl Acetate DM06HG5 Moderate Additive CNS depression effects by the combination of Propantheline and Levomethadyl Acetate. Opioid use disorder [6C43] [15]
Oxymorphone DM65AGJ Moderate Additive antimotility effects by the combination of Propantheline and Oxymorphone. Pain [MG30-MG3Z] [16]
Levorphanol DMGS80V Moderate Additive CNS depression effects by the combination of Propantheline and Levorphanol. Pain [MG30-MG3Z] [16]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Propantheline and Dezocine. Pain [MG30-MG3Z] [8]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Propantheline and Flavoxate. Pain [MG30-MG3Z] [10]
Nalbuphine DMOSQGU Moderate Additive CNS depression effects by the combination of Propantheline and Nalbuphine. Pain [MG30-MG3Z] [16]
Buprenorphine DMPRI8G Moderate Additive antimotility effects by the combination of Propantheline and Buprenorphine. Pain [MG30-MG3Z] [16]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Propantheline and Hydrocodone. Pain [MG30-MG3Z] [8]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Propantheline and Biperiden. Parkinsonism [8A00] [10]
Levodopa DMN3E57 Moderate Altered absorption of Propantheline due to GI dynamics variation caused by Levodopa. Parkinsonism [8A00] [26]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Propantheline and Orphenadrine. Parkinsonism [8A00] [10]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Propantheline and Methylscopolamine. Peptic ulcer [DA61] [10]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Propantheline and Levomepromazine. Psychotic disorder [6A20-6A25] [10]
Quetiapine DM1N62C Moderate Additive anticholinergic effects by the combination of Propantheline and Quetiapine. Schizophrenia [6A20] [10]
Mesoridazine DM2ZGAN Moderate Additive anticholinergic effects by the combination of Propantheline and Mesoridazine. Schizophrenia [6A20] [10]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Propantheline and Aripiprazole. Schizophrenia [6A20] [10]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Propantheline and Iloperidone. Schizophrenia [6A20] [10]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Propantheline and Paliperidone. Schizophrenia [6A20] [10]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Propantheline and Perphenazine. Schizophrenia [6A20] [10]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Propantheline and Molindone. Schizophrenia [6A20] [10]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Propantheline and Thiothixene. Schizophrenia [6A20] [10]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Propantheline and Trifluoperazine. Schizophrenia [6A20] [10]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Propantheline and Asenapine. Schizophrenia [6A20] [10]
Pimozide DMW83TP Moderate Additive anticholinergic effects by the combination of Propantheline and Pimozide. Schizophrenia [6A20] [10]
Fentanyl DM8WAHT Moderate Additive antimotility effects by the combination of Propantheline and Fentanyl. Sensation disturbance [MB40] [16]
Pramlintide DM0EZ9Q Moderate Altered absorption of Propantheline due to GI dynamics variation caused by Pramlintide. Type-1/2 diabete [5A10-5A11] [27]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Propantheline and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [10]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Propantheline and Methdilazine. Vasomotor/allergic rhinitis [CA08] [10]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Propantheline and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [9]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Propantheline and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [10]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Propantheline and Acrivastine. Vasomotor/allergic rhinitis [CA08] [10]
⏷ Show the Full List of 90 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Calcium carbonate E00198 10112 Binding agent; Buffering agent; Diluent; Opacifying agent
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium carbonate E00205 11029 Adsorbent; Diluent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Shellac E00695 Not Available Coating agent; Film/membrane-forming agent; Microencapsulating agent; Modified-release agent
⏷ Show the Full List of 17 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Propantheline 15 mg tablet 15 mg Oral Tablet Oral
Propantheline 7.5 mg tablet 7.5 mg Oral Tablet Oral
Propantheline Bromide 15mg tablet 15mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 329).
2 Propantheline FDA Label
3 BDDCS applied to over 900 drugs
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Involvement of the peripheral cholinergic muscarinic system in the compensatory ovarian hypertrophy in the rat. Exp Biol Med (Maywood). 2004 Sep;229(8):793-805.
6 Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
7 Cerner Multum, Inc. "Australian Product Information.".
8 Product Information. Levorphanol Tartrate (levorphanol). Sentynl Therapeutics, Solana Beach, CA.
9 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
10 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
11 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
12 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
13 Multum Information Services, Inc. Expert Review Panel.
14 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
15 Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
16 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
17 Product Information. GenESA (arbutamine). Gensia Inc, San Diego, CA.
18 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
19 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20 Fleseriu M, Auchus R, Pivonello R, et al. "Levoketoconazole: a novel treatment for endogenous Cushing's syndrome.".
21 Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
22 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
23 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
24 Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
25 Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
26 Algeri S, Cerletti C, Curcio M, et al. "Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and man." Eur J Pharmacol 35 (1976): 293-9. [PMID: 1248506]
27 Product Information. Symlin (pramlintide). Amphastar Pharmaceuticals Inc, South El Monte, CA.